NLRP3 and metabolic dysfunction-associated steatohepatitis: This study suggested that the mechanism of CA treatment for NASH is to inhibit the activation of the NLRP3 inflammasome signaling pathway by increasing the expression of MARCKS (Song et al., 2018).